REXULTI® (brexpiprazole) agitation that may happen with dementia due to Alzheimer's disease

Discover the only FDA-Approved treatment for agitation that may happen with dementia due to Alzheimer’s disease. See Important Safety Info and Full Prescribing Info, including Boxed WARNING.

Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

REXULTI® (brexpiprazole), Agitation associated with dementia due to Alzheimer's disease

Important News for Older Adults: FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer's Disease - Alliance for Aging Research

Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® ( brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

Lundbeck: Alzheimer's agitation drug can make a real difference — MedWatch

Insights & Implications in Gerontology: Agitation in Alzheimer's Disease by GSAStrategicAlliances - Issuu

FDA Approves Rexulti for Treating Agitation Due to Alzheimer's - MyChesCo

Agitation in Alzheimer's: Rexulti® Makes Meaningful Improvements

FDA nod for Rexulti sNDA in treatment of Alzheimer's agitation

FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's disease agitation

REXULTI® (brexpiprazole) Patient Information Website